Zymeworks (ZYME) Stock Analysis: AI Score & Alternative Data
ZYME alt-data: web traffic climbing, job postings lagging
Is Zymeworks a buy right now? The alternative data says hold. This ZYME stock analysis is built on the 25+ alternative data signals AltIndex tracks on Zymeworks every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 50/100: a Hold. The stock trades at $29.63 with a $2B market cap.
The bullish side of the 90-day ledger: web traffic up 16.1% to 41K monthly visits. The drag: job postings down 22.2% to 7 open roles, and just 46% of employees report a positive business outlook. That tension is what keeps the score mid-range.
ZYME’s broader alt-data profile also covers headcount (266 employees, according to LinkedIn), X followers (1K), and Reddit mentions (1 a day). Every signal links to its own page with full history, the ZYME technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ZYME is just below.
Zymeworks AI Stock Analysis
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is dedicated to the development of therapeutic treatments for cancer. The company leverages its proprietary platform to design antibodies and other protein therapeutics, which are aimed at improving patient outcomes and quality of life.
Analysis generated October 1, 2026.
Recent Zymeworks Stock Alerts
![]() |
Zymeworks | November 5 Price is down by -6.1% in the last 24h. |
![]() |
Zymeworks | October 20 Price is up by 6.1% in the last 24h. |
![]() |
Zymeworks | October 11 Insider Alert: Schayowitz Adam is selling shares |
![]() |
Zymeworks | August 26 Price is up by 7.3% in the last 24h. |
Zymeworks Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 41K | 16.1% | |
| Job Posts | 7 | 22.2% | |
| LinkedIn Employees | 266 | 1.8% | |
| Employee Recommend | 51 | 0% | |
| Business Outlook | 46 | 2.1% | |
| Sentiment | 0 | 100.0% | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 3 | 200.0% | |
| Stocktwits Mentions | 7 | 22.2% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 3K | 1.5% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 1K | 0.5% |
About Zymeworks (ZYME)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Price | $29.63 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2B |
| Year Range | $16 – $31 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Zymeworks News
View more →
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026October 23 - Financial Post |
|
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3October 23 - Financial Post |
|
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaOctober 19 - Financial Post |
|
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsOctober 15 - Financial Post |
|
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionSeptember 28 - Financial Post |
See Zymeworks’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ZYME, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEZymeworks Earnings & Financial Performance
View all earnings →Zymeworks Insider Trading Activity
View all →| Schayowitz Adam filed to sell 23,205 shares at $0.0. Oct 9 '26 |
| Moore Paul Andrew filed to sell 48,497 shares at $0.0. Jan 12 '26 |
| Smith Jeffrey T L filed to sell 26,708 shares at $0.0. Jan 12 '26 |
| Hollywood Mark filed to sell 132,913 shares at $0.0. Jan 12 '26 |
| Galbraith Kenneth filed to sell 226,842 shares at $0.0. Jan 12 '26 |
Zymeworks Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Zymeworks
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
![]() |
Trevi TherapeuticsTRVI |
$14.33 11.9% | $2B | 64 |
![]() |
Vir BiotechnologyVIR |
$12.21 10.8% | $2B | 47 |
![]() |
ImmunomeIMNM |
$18.71 4.5% | $2B | 57 |
![]() |
Recursion PharmaceuticalsRXRX |
$3.52 0.6% | $2B | 47 |
![]() |
BiohavenBHVN |
$14.48 4.2% | $2B | 52 |
Explore Zymeworks Data
Frequently Asked Questions: Zymeworks (ZYME)
Zymeworks has an AltIndex AI Score of 50/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
50/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Zymeworks (ZYME) stock is $29.63 with a market cap of $2B.
As of today, Zymeworks’s PE (Price to Earnings) ratio is —.
View the latest Zymeworks insider transactions to see recent buying and selling activity by company executives and directors.
Check the Zymeworks congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ZYME stock price chart above shows Zymeworks’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Zymeworks technical analysis for RSI, moving averages, and more.
See the stocks similar to Zymeworks section on this page for companies in the same industry ranked by market cap and AI Score.




